MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Moderna, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$226.89+8.88 (+4.07%)
Close on Oct 19, 2026
- Market cap
- $90.30B
- P/E (TTM)
- –
- Dividend yield
- –
Moderna, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $1.82B | $3.11B | $6.67B | $18.44B | $17.68B | $200.00M | $0 | $0 | – | – | 93.5% | -41.5% |
| COVID | $1.81B | $3.08B | $6.67B | $18.44B | – | – | – | – | – | – | 93.1% | -41.3% |
| Other revenue | $126.00M | $127.00M | $177.00M | $828.00M | $796.00M | – | – | – | – | – | 6.5% | -0.8% |
| Stand-ready manufacturing revenue | $80.00M | $0 | $0 | – | – | – | – | – | – | – | 4.1% | – |
| Grant revenue | $22.00M | $37.00M | $94.00M | $388.00M | $735.00M | $529.00M | $12.00M | $12.56M | $28.85M | $6.86M | 1.1% | -40.5% |
| Collaboration revenue (Note 5) | $13.00M | $48.00M | $83.00M | $440.00M | $61.00M | $74.00M | $48.00M | – | – | – | 0.7% | -72.9% |
| Licensing and royalty revenue | $11.00M | $42.00M | $0 | $0 | – | – | – | – | – | – | 0.6% | -73.8% |
| RSV | $8.00M | $25.00M | $0 | $0 | – | – | – | – | – | – | 0.4% | -68.0% |
| Collaboration revenue | – | – | – | $440.00M | $61.00M | $74.00M | $48.00M | $122.51M | $146.95M | $69.11M | – | – |
| Collaboration revenue from related party | – | – | – | – | – | – | $5.23M | $45.99M | $30.02M | $32.43M | – | – |
| Collaboration revenue from related party | – | – | – | – | – | – | $5.23M | $45.99M | $30.02M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.20B | $1.79B | $1.90B | $5.15B | $6.18B | $764.00M | $55.00M | $89.08M | – | – | 61.7% | -32.8% |
| Rest of world | $692.00M | $853.00M | $3.60B | $7.30B | $5.45B | $6.00M | $0 | – | – | – | 35.6% | -18.9% |
| Europe | $53.00M | $598.00M | $1.36B | $6.82B | $6.85B | $33.00M | $5.00M | – | – | – | 2.7% | -91.1% |
| Rest of world | – | – | – | – | – | $38.87M | $5.23M | $45.99M | – | – | – | – |
From the segment and revenue-disaggregation notes of Moderna's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.